95 related articles for article (PubMed ID: 27213811)
21. Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin.
Mittal K; Cooper GW; Lee BP; Su Y; Skinner KT; Shim J; Jonus HC; Kim WJ; Doshi M; Almanza D; Kynnap BD; Christie AL; Yang X; Cowley GS; Leeper BA; Morton CL; Dwivedi B; Lawrence T; Rupji M; Keskula P; Meyer S; Clinton CM; Bhasin M; Crompton BD; Tseng YY; Boehm JS; Ligon KL; Root DE; Murphy AJ; Weinstock DM; Gokhale PC; Spangle JM; Rivera MN; Mullen EA; Stegmaier K; Goldsmith KC; Hahn WC; Hong AL
Commun Biol; 2024 Apr; 7(1):426. PubMed ID: 38589567
[TBL] [Abstract][Full Text] [Related]
22. Exploiting embryonic niche conditions to grow Wilms tumor blastema in culture.
Wojcik HM; Lovvorn HN; Hollingshead M; Pierce J; Stotler H; Murphy AJ; Borgel S; Phelps HM; Correa H; Perantoni AO
Front Oncol; 2023; 13():1091274. PubMed ID: 37007076
[TBL] [Abstract][Full Text] [Related]
23. Gene expression studies of WT1 mutant Wilms tumor cell lines in the frame work of published kidney development data reveals their early kidney stem cell origin.
Royer-Pokora B; Wruck W; Adjaye J; Beier M
PLoS One; 2023; 18(1):e0270380. PubMed ID: 36689432
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive Biology and Genetics Compendium of Wilms Tumor Cell Lines with Different
Royer-Pokora B; Busch MA; Tenbusch S; Schmidt M; Beier M; Woods AD; Thiele H; Mora J
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33379206
[TBL] [Abstract][Full Text] [Related]
25. Chromosomal Heterogeneity of the G-401 Rhabdoid Tumor Cell Line: Unusual Partial 7p Trisomy.
Fasler-Kan E; Aliu N; Haecker FM; Maltsev N; Ruggiero S; Cholewa D; Bartenstein A; Milošević M; Berger SM
Front Med (Lausanne); 2019; 6():187. PubMed ID: 31544104
[TBL] [Abstract][Full Text] [Related]
26. Safety evaluation of conditionally immortalized cells for renal replacement therapy.
Mihajlovic M; Hariri S; Westphal KCG; Janssen MJ; Oost MJ; Bongiovanni L; van den Heuvel LP; de Bruin A; Hilbrands LB; Masereeuw R
Oncotarget; 2019 Sep; 10(51):5332-5348. PubMed ID: 31523392
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy and terminal skeletal muscle differentiation in WT1-mutant Wilms tumors.
Royer-Pokora B; Beier M; Brandt A; Duhme C; Busch M; de Torres C; Royer HD; Mora J
Cancer Med; 2018 Apr; 7(4):1359-1368. PubMed ID: 29542868
[TBL] [Abstract][Full Text] [Related]
28. The role of Wilms' tumor genes.
Hirose M
J Med Invest; 1999 Aug; 46(3-4):130-40. PubMed ID: 10687307
[TBL] [Abstract][Full Text] [Related]
29. WT1: a novel tumor suppressor gene inactivated in Wilms' tumor.
Haber DA; Buckler AJ
New Biol; 1992 Feb; 4(2):97-106. PubMed ID: 1313285
[TBL] [Abstract][Full Text] [Related]
30. Establishment of a Conditionally Immortalized Wilms Tumor Cell Line with a Homozygous WT1 Deletion within a Heterozygous 11p13 Deletion and UPD Limited to 11p15.
Brandt A; Löhers K; Beier M; Leube B; de Torres C; Mora J; Arora P; Jat PS; Royer-Pokora B
PLoS One; 2016; 11(5):e0155561. PubMed ID: 27213811
[TBL] [Abstract][Full Text] [Related]
31. Stratification of Wilms tumor by genetic and epigenetic analysis.
Scott RH; Murray A; Baskcomb L; Turnbull C; Loveday C; Al-Saadi R; Williams R; Breatnach F; Gerrard M; Hale J; Kohler J; Lapunzina P; Levitt GA; Picton S; Pizer B; Ronghe MD; Traunecker H; Williams D; Kelsey A; Vujanic GM; Sebire NJ; Grundy P; Stiller CA; Pritchard-Jones K; Douglas J; Rahman N
Oncotarget; 2012 Mar; 3(3):327-35. PubMed ID: 22470196
[TBL] [Abstract][Full Text] [Related]
32. Infrequent mutation of the WT1 gene in 77 Wilms' Tumors.
Gessler M; König A; Arden K; Grundy P; Orkin S; Sallan S; Peters C; Ruyle S; Mandell J; Li F
Hum Mutat; 1994; 3(3):212-22. PubMed ID: 8019557
[TBL] [Abstract][Full Text] [Related]
33. Deletion of WT1 and WIT1 genes and loss of heterozygosity on chromosome 11p in Wilms tumors in Japan.
Kaneko Y; Takeda O; Homma C; Maseki N; Miyoshi H; Tsunematsu Y; Williams BG; Saunders GF; Sakurai M
Jpn J Cancer Res; 1993 Jun; 84(6):616-24. PubMed ID: 8393432
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathologic correlates of loss of heterozygosity in Wilm's tumor: a preliminary analysis.
Grundy P; Telzerow P; Moksness J; Breslow NE
Med Pediatr Oncol; 1996 Nov; 27(5):429-33. PubMed ID: 8926924
[TBL] [Abstract][Full Text] [Related]
35. Identical genetic changes in different histologic components of Wilms' tumors.
Zhuang Z; Merino MJ; Vortmeyer AO; Bryant B; Lash AE; Wang C; Deavers MT; Shelton WF; Kapur S; Chandra RS
J Natl Cancer Inst; 1997 Aug; 89(15):1148-52. PubMed ID: 9262253
[TBL] [Abstract][Full Text] [Related]
36. The IGF signalling pathway in Wilms tumours--a report from the ENCCA Renal Tumours Biology-driven drug development workshop.
Maschietto M; Charlton J; Perotti D; Radice P; Geller JI; Pritchard-Jones K; Weeks M
Oncotarget; 2014 Sep; 5(18):8014-26. PubMed ID: 25478630
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
